Guggenheim 3rd Annual Healthcare Innovation Conference - SAGIMET BIOSCIENCES INC

Financial Performance:

• Raised $175 million in April 2026 to extend runway into 2028.
• Recently secured an additional $115 million via a reverse inquiry.
• Current capitalization funds the initiation of the second oral FAST inhibitor and the development of a topical FAST inhibitor.
• No specific revenue or profit margin figures provided as the company is pre-commercial; funding is directed toward clinical development and trials.

Guidance and Future Outlook:

• Denny (Oral FAST Inhibitor): Primary endpoint results for the U.S. Phase 3 trial (800 patients) are expected by the end of 2027.
• Second Oral Asset: Phase 2 data anticipated around the same time as the Denny Phase 3 readout (end of 2027).
• Topical Asset: Human testing scheduled for 2028, targeting mild acne patients.
• Strategic Focus: Full pivot to dermatology programs initiated in April; molecule is well-characterized with a strong safety profile enabling study in adolescents.

Business Segments and Product Lines:

• Primary Product (Denny): An oral fatty acid synthase (FAS) inhibitor targeting sebum production and inflammation; designed to replace oral antibiotics and topical retinoids.
• Pipeline Assets:
  • Second Oral Inhibitor: More potent than Denny; currently in Phase 2 with data expected in 2027.
  • Topical Inhibitor: In formulation development; aims to penetrate skin layers for mild acne cases.
• Strategic Pivot: Shifted focus from hepatology/MASH to dermatology/acne following favorable FDA interactions and robust clinical data from Chinese partner (Scletus/Ascletus).

Market and Competitive Landscape:

• Market Size: ~50 million U.S. acne patients; 10–15 million with moderate-to-severe acne requiring treatment beyond current options.
• Competitive Differentiation: FAS inhibition is highly specific (targeting sebocytes), avoiding the systemic side effects of antiandrogens and the resistance/toxicity issues associated with antibiotics and isotretinoin (Accutane).
• Market Positioning: Management expects Denny to:
  • Dramatically reduce or replace oral antibiotics.
  • Displace topical therapies (especially for truncal acne).
  • Serve as a prerequisite step before patients qualify for isotretinoin.
• Adolescent Focus: FDA encouragement to include 12–17-year-olds expands the treatable patient population significantly.

Risks and Challenges:

• Regulatory: Reliance on FDA approval of the specific trial design (adolescent inclusion) and labeling claims derived from Open-Label Extension (OLE) long-term safety data.
• Compliance: While management expects non-compliance to be low (1–2%) due to trial monitoring and "smart caps" on pill bottles, adolescent compliance remains a standard clinical trial consideration.
• Competitive: No head-to-head trials exist yet; success relies on clinical efficacy surpassing existing standards of care numerically.
• Development: Uncertainty regarding whether the more potent second oral inhibitor will improve efficacy or simply enhance tolerability.

Management Commentary and Tone:

• Tone: Highly confident and enthusiastic; management views the strategic pivot as "well-received" by the market and investors.
• Clinical Confidence: Emphasizes the "unique" rapidity of effect (visible at 2 weeks, significant at 4 weeks) compared to other sebum reducers (12 weeks).
• Safety: Highlights excellent tolerability profile from Chinese data (20% IGA improvement, 20% lesion reduction at 12 weeks; 80% reduction in inflammatory lesions at 52 weeks) and low rates of adverse events (dry skin, dry eye).
• Market Reaction: Reports "enthusiasm" from Key Opinion Leaders (KOLs) and the broader dermatology community.

Analyst Questions and Answers:

• Q: How does FAS inhibition differentiate from other mechanisms?
  • A: It specifically inhibits fatty acid synthase in sebocytes, addressing two of four acne drivers (sebum and inflammation) without the systemic effects of antiandrogens or the complexity of retinoids.
• Q: What do the Chinese Phase 3 data show?
  • A: 480 patients showed highly significant IGA success (~20%) and lesion score reductions (~20%) at 12 weeks; effects increased over 52 weeks with robust safety.
• Q: How will the U.S. Phase 3 trial be executed and timed?
  • A: 800 patients (450 adolescents, 350 adults); dosed first patient Oct 21; 6-month enrollment; primary data end of 2027. Smart caps will monitor adherence.
• Q: Will the OLE data support labeling?
  • A: Key efficacy claims will come from the 12-week placebo-controlled phase; OLE will primarily support long-term safety claims and potentially be referenced in the label.
• Q: What is the outlook for the second oral and topical assets?
  • A: Second oral is ~2x more potent; topical is in formulation targeting mild acne; human data for both expected in 2027-2028.

Other Key Points:

• The FDA specifically cross-referenced the acne IND with the MASH (Metabolic dysfunction-associated Steatohepatitis) division, validating the molecule's safety profile.
• The company utilizes a two-to-one randomization for adolescent patients (300 drug, 150 placebo) within the larger 800-patient trial.
• Management anticipates the drug to be used for extended periods, given the chronic nature of acne (often >10 years duration).
• The company plans to include a significant number of adolescent patients in the Open-Label Extension to meet agency expectations.